TrovaGene Inc. (TROV)

3.10
0.01 0.32
NASDAQ : Health Technology
Prev Close 3.11
Open 3.13
Day Low/High 3.06 / 3.16
52 Wk Low/High 2.54 / 20.26
Volume 46.59K
Avg Volume 1.19M
Exchange NASDAQ
Shares Outstanding 5.42M
Market Cap 16.70M
EPS -8.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Trovagene Announces Data Demonstrating Significant Synergy Of Onvansertib In Combination With Venetoclax In Cell Model Of Venetoclax-Resistant AML

Trovagene Announces Data Demonstrating Significant Synergy Of Onvansertib In Combination With Venetoclax In Cell Model Of Venetoclax-Resistant AML

Data provides support for clinical evaluation of onvansertib in combination with venetoclax in patients with difficult-to-treat relapsed or refractory acute myeloid leukemia (AML)

Trovagene Announces Update To Phase 1b/2 AML Trial Data Presented At AACR - Additional Patients Achieve Complete Response At Two Highest Dose Levels Of Onvansertib

Trovagene Announces Update To Phase 1b/2 AML Trial Data Presented At AACR - Additional Patients Achieve Complete Response At Two Highest Dose Levels Of Onvansertib

Complete response achieved in 3 of 6 (50%) evaluable patients at the highest doses (27mg/m2 and 40mg/m2) of onvansertib in combination with standard-of-care decitabine

Trovagene Announces $1.5 Million Equity Investment At Premium To Market From Institutional Investor, Lincoln Park Capital

Trovagene Announces $1.5 Million Equity Investment At Premium To Market From Institutional Investor, Lincoln Park Capital

Investment follows recent receipt of ~$3.2 million from exercise of previously issued warrants

Early Data From Phase 2 Trial Indicates Activity Of Onvansertib In Prostate Cancer Patients Showing Initial Resistance To Anti-Androgen Therapy

Early Data From Phase 2 Trial Indicates Activity Of Onvansertib In Prostate Cancer Patients Showing Initial Resistance To Anti-Androgen Therapy

Early PSA response observed when onvansertib is added to abiraterone (Zytiga®) in 2 of 6 patients to-date; first patient achieves primary efficacy endpoint

Phase 1b/2 Dose Escalation Trial Of Onvansertib In Relapsed/Refractory AML Demonstrates Safety, Tolerability And Relative Durability With Complete Responses At Highest Dose Levels

Phase 1b/2 Dose Escalation Trial Of Onvansertib In Relapsed/Refractory AML Demonstrates Safety, Tolerability And Relative Durability With Complete Responses At Highest Dose Levels

Greatest anti-leukemic activity has been observed in the onvansertib + decitabine arm, with complete response in 2 of 4 (50%) of evaluable patients from the two highest dose levels

Trovagene Receives Approximately $3.0 Million From Exercise Of Warrants

Trovagene Receives Approximately $3.0 Million From Exercise Of Warrants

SAN DIEGO, March 13, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas...

Trovagene Regains Compliance With Nasdaq Listing Requirements

Trovagene Regains Compliance With Nasdaq Listing Requirements

SAN DIEGO, March 12, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas...

Trovagene Announces Fourth Quarter And Full-Year 2018 Results

Trovagene Announces Fourth Quarter And Full-Year 2018 Results

SAN DIEGO, March 6, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and...

Trovagene, Inc. Announces Reverse Stock Split

Trovagene, Inc. Announces Reverse Stock Split

Reverse stock split intended to bring company into compliance with minimum bid price requirement for maintaining listing on Nasdaq Capital Market

Trovagene Presents Update On Phase 2 Study Of Onvansertib In Combination With Zytiga In Patients With MCRPC At ASCO-GU Conference

Trovagene Presents Update On Phase 2 Study Of Onvansertib In Combination With Zytiga In Patients With MCRPC At ASCO-GU Conference

Safety lead-in completed, no overlapping toxicities, combination is safe and well tolerated

Trovagene And PoC Capital Enter Agreement To Fund Clinical Development Of Onvansertib In Metastatic Colorectal Cancer (mCRC)

Trovagene And PoC Capital Enter Agreement To Fund Clinical Development Of Onvansertib In Metastatic Colorectal Cancer (mCRC)

Trovagene receives "may proceed" notification from FDA for Phase 1b/2 trial of Onvansertib in combination with standard-of-care in patients with mCRC harboring KRAS mutations

Trovagene Announces New Patent Issued For Combination Of Onvansertib With Anti-Androgen Drugs To Treat Non-Metastatic And Metastatic Prostate Cancer

Trovagene Announces New Patent Issued For Combination Of Onvansertib With Anti-Androgen Drugs To Treat Non-Metastatic And Metastatic Prostate Cancer

Broad patent covers anti-androgen or androgen antagonist drugs, including combination treatment with Zytiga®, Xtandi® and Erleada® in multibillion-dollar market

New Data From Phase 1b/2 Study Of Onvansertib In Combination With LDAC Or Decitabine Demonstrates Response To Treatment In Relapsed/Refractory AML

New Data From Phase 1b/2 Study Of Onvansertib In Combination With LDAC Or Decitabine Demonstrates Response To Treatment In Relapsed/Refractory AML

- Preliminary Anti-Leukemic Activity Demonstrates >80% Response to Treatment with Onvansertib in Combination with Low-Dose Cytarabine (LDAC) or Decitabine in Dose Escalation Phase 1b of Trial

Short Interest Expands By 14.2% For TROV

The most recent short interest data has been released for the 05/31/2017 settlement date, which shows a 442,930 share increase in total short interest for TrovaGene Inc , to 3,567,833, an increase of 14.17% since 05/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Short Interest Moves 16.3% Higher For TROV

The most recent short interest data has been released for the 04/28/2017 settlement date, which shows a 460,990 share increase in total short interest for TrovaGene Inc , to 3,292,918, an increase of 16.28% since 04/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

TrovaGene (TROV) Is Today's Strong On High Volume Stock

TrovaGene (TROV) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified TrovaGene (TROV) as a strong on high relative volume candidate

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Trovagene, Inc. - TROV

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Trovagene, Inc. - TROV

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Trovagene, Inc.

Short Interest Jumps 17.6% For TROV

Short Interest Jumps 17.6% For TROV

The most recent short interest data has been released by the NASDAQ for the 02/12/2016 settlement date, which shows a 697,508 share increase in total short interest for TrovaGene Inc , to 4,657,297, an increase of 17.61% since 01/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Here’s Why TrovaGene (TROV) Stock is Soaring Today

Here’s Why TrovaGene (TROV) Stock is Soaring Today

TrovaGene (TROV) stock is spiking on Monday afternoon as the company enters an agreement with FedMed for access to cancer monitoring tests and services.

TrovaGene (TROV) Is Weak On High Volume Today

TrovaGene (TROV) Is Weak On High Volume Today

Trade-Ideas LLC identified TrovaGene (TROV) as a weak on high relative volume candidate

Trovagene (TROV) Stock Soars on America's Choice Provider Network Partnership

Trovagene (TROV) Stock Soars on America's Choice Provider Network Partnership

Trovagene (TROV) stock is climbing on heavy trading volume on Thursday after the company announced a partnership with America's Choice Provider Network.

Oversold Conditions For TrovaGene (TROV)

Oversold Conditions For TrovaGene (TROV)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TROV: Insiders vs. Shorts

TROV: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 11/30/2015 settlement date, and TrovaGene Inc is one of the most shorted stocks of the Russell 3000, based on 8.86 "days to cover" versus the median component at 6.38. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Interesting TROV Put And Call Options For July 2016

Interesting TROV Put And Call Options For July 2016

Investors in TrovaGene Inc saw new options begin trading this week, for the July 2016 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

First Week of TROV December 18th Options Trading

First Week of TROV December 18th Options Trading

Investors in TrovaGene Inc saw new options become available this week, for the December 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TROV options chain for the new December 18th contracts and identified the following call contract of particular interest.

TheStreet Quant Rating: D- (Sell)